StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.08−0.66 (-3.52%)

Close on Nov 16, 2026Market cap $2.89BP/E –Yield –

Denali Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Denali Therapeutics's profit margin for the twelve months ending Jun 30, 2024 was -33121.9%. For fiscal 2023 it was -43.9%, against -300.6% the year before. The highest annual figure on record is 21.2% in fiscal 2020.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-43.9%+256.6
FY2022Dec 31, 2022-300.6%+296.6
FY2021Dec 31, 2021-597.2%−618.3
FY2020Dec 31, 202021.2%+761.9
FY2019Dec 31, 2019-740.7%−712.7
FY2018Dec 31, 2018-28.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-3539.2%−2579.6
Q3 FY2023Sep 30, 2023-7841.6%−4939.1
Q2 FY2023Jun 30, 202362.3%+174.4
Q1 FY2023Mar 31, 2023-312.4%−157.6
Q4 FY2022Dec 31, 2022-959.6%−358.2
Q3 FY2022Sep 30, 2022-2902.5%−1301.9
Q2 FY2022Jun 30, 2022-112.0%+152.5
Q1 FY2022Mar 31, 2022-154.8%+729.3
Q4 FY2021Dec 31, 2021-601.4%−678.7
Q3 FY2021Sep 30, 2021-1600.5%−980.6
Q2 FY2021Jun 30, 2021-264.6%+740.3
Q1 FY2021Mar 31, 2021-884.0%+691.0
Q4 FY2020Dec 31, 202077.3%+1233.7
Q3 FY2020Sep 30, 2020-619.9%−279.9
Q2 FY2020Jun 30, 2020-1004.9%+385.0
Q1 FY2020Mar 31, 2020-1575.0%−647.7
Q4 FY2019Dec 31, 2019-1156.4%−1218.0
Q3 FY2019Sep 30, 2019-340.0%+2619.9
Q2 FY2019Jun 30, 2019-1390.0%+1930.7
Q1 FY2019Mar 31, 2019-927.3%+2766.6
Q4 FY2018Dec 31, 201861.7%–
Q3 FY2018Sep 30, 2018-2959.9%–
Q2 FY2018Jun 30, 2018-3320.6%–
Q1 FY2018Mar 31, 2018-3693.9%–

More Denali Therapeutics figures

See a number that looks wrong?